Fast Forwarding Checkpoint Medicine
Striving to improve the quality of life by introducing the latest in
medical technology for treating cancer and autoimmunity.
Striving to improve the quality of life by introducing the latest in medical technology for treating cancer and autoimmunity.
What we do
Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.
The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
Our Focus
The Company’s primary program is focused on developing modulators of NR2F6, an immune checkpoint for which the Company has a strong patent portfolio. NR2F6 is becoming recognized as a key regulator of T cell function. NR2F6 is anorphan nuclear receptor which naturally suppresses the Nuclear Factor of activated T-cells (“NFAT”) and cytokines that require NFAT for expression including IL-18, IL-17 and IL-2. Regen is currently developing RNA and small molecule drugs that activate or inhibit NR2F6, as well as CAR-T cells genetically modifiedwith NR2F6 blocked. These drugs will be tested for efficacy in various cancersand autoimmune disorders
KimerApt
Regen has designed a platform technology that uses aptamers that have dual functionality. Aptamers are DNA or RNA sequences that can bind to and inhibit receptors just like antibodies.
DuraCAR
Regen has filed patents on shRNA that is designed to inhibit NR2F6 expression in CAR-T Cells and make these CAR-T cells have long-term, durable effectiveness.
dCellVax/tCellVax
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
KimerApt
Regen has designed a platform technology that uses aptamers that have dual functionality. Aptamers are DNA or RNA sequences that can bind to and inhibit receptors just like antibodies.
DuraCAR
Regen has filed patents on shRNA that is designed to inhibit NR2F6 expression in CAR-T Cells and make these CAR-T cells have long-term, durable effectiveness.
dCellVax
dCellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
Product Pipeline
Regen BioPharma has a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs. All of the technologies are protected by multiple granted and pending patents
KimerApt
Regen has designed a platform technology that uses aptamers that have dual functionality. Aptamers are DNA or RNA sequences that can bind to and inhibit receptors just like antibodies. PAM is a critical region for Aptamer inhibition.
DuraCAR
Regen has filed patents on shRNA that is designed to inhibit NR2F6 expression in CAR-T Cells and make these CAR-T cells have long-term, durable effectiveness.
dCellVax
dCellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
Investor Relations
Regen BioPharma, Inc., is a publicly traded biotechnology company (OTCPINK: RGBP) and (OTCPINK: RGBPP)focused on developing innovative treatments using autologous cell therapies, RNA-and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmunity space.
Investor Relations
Regen BioPharma, Inc., is a publicly traded biotechnology company (OTCPINK: RGBP) and (OTCPINK: RGBPP)focused on developing innovative treatments using autologous cell therapies, RNA-and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmunity space.